• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by Huber Reid M

    8/12/21 8:41:00 PM ET
    $BCTG
    Business Services
    Finance
    Get the next $BCTG alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Huber Reid M

    (Last) (First) (Middle)
    C/O TANGO THERAPEUTICS, INC.
    100 BINNEY STREET, SUITE 700

    (Street)
    CAMBRIDGE MA 02142

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/10/2021
    3. Issuer Name and Ticker or Trading Symbol
    Tango Therapeutics, Inc. [ TNGX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24: Power of Attorney
    No securities are beneficially owned.
    By: /s/ Daniella Beckman, as attorney-in-fact 08/12/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCTG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCTG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCTG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: Boxer Capital, LLC claimed ownership of 6,973,166 units of Common Stock

    3 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    8/20/21 4:30:38 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form 3: BCTG Holdings, LLC claimed ownership of 6,988,450 units of Common Stock

    3 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    8/20/21 4:31:02 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form 4 filed by Beckman Daniella

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    8/16/21 7:00:32 PM ET
    $BCTG
    Business Services
    Finance

    $BCTG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies

    – Business combination transaction with BCTG Acquisition Corp., a special purpose acquisition company sponsored by Boxer Capital, completed today – – Combined company Tango Therapeutics, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "TNGX" – – Total expected cash position of approximately $515 million including gross proceeds from transaction totaling approximately $342 million, combining funds held in BCTG's trust account and PIPE financing once completed – CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango Therapeutics" or "Tango"), a biotechnology company committed to discovering and delivering the next generation of prec

    8/10/21 9:00:00 AM ET
    $BCTG
    Business Services
    Finance

    Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies

    - Leading institutional investors commit $186 million through a common stock private investment in public equity ("PIPE") led by Boxer Capital - Total proceeds expected to be approximately $353 million, combining funds held in trust by BCTG Acquisition Corp and the PIPE financing - Merger expected to be completed in third quarter of 2021, and Combined Company will be listed on Nasdaq under the ticker "TNGX" – - Joint investor conference call to discuss the proposed transaction today, Wednesday, April 14, at 10:00 a.m. ET – Tango Therapeutics, a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, and BCTG Acquisition Corp. (NA

    4/14/21 8:30:00 AM ET
    $BCTG
    Business Services
    Finance

    $BCTG
    SEC Filings

    View All

    SEC Form S-8 filed by BCTG Acquisition Corp.

    S-8 - Tango Therapeutics, Inc. (0001819133) (Filer)

    10/14/21 5:30:07 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form 424B3 filed by BCTG Acquisition Corp.

    424B3 - Tango Therapeutics, Inc. (0001819133) (Filer)

    10/7/21 8:18:28 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form EFFECT filed by BCTG Acquisition Corp.

    EFFECT - Tango Therapeutics, Inc. (0001819133) (Filer)

    9/30/21 12:15:16 AM ET
    $BCTG
    Business Services
    Finance

    $BCTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BCTG Acquisition Corp.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    9/10/21 12:17:18 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form SC 13D filed by BCTG Acquisition Corp.

    SC 13D - Tango Therapeutics, Inc. (0001819133) (Subject)

    8/20/21 4:31:07 PM ET
    $BCTG
    Business Services
    Finance

    SEC Form SC 13G filed by BCTG Acquisition Corp.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    8/19/21 4:59:28 PM ET
    $BCTG
    Business Services
    Finance